Aboriginal Cardiovascular Omega 3 Trial

The Aboriginal Cardiovascular Omega 3 Trial seeks to identify if Aboriginal people with heart disease are protected from subsequent heart attacks by taking an Omega 3 supplement, and the mechanisms which occur.

Lead Organisation:


Collaborating Organisations:

Wardliparingga Aboriginal Research Unit, SAHMRI

Vascular Research Centre, SAHMRI

University of Adelaide

Project Overview:

Despite high cardiovascular (CV) mortality among Aboriginal and Torres Strait Islander people, few intervention trials have sought to evaluate novel approaches to reducing differential outcomes. Research to date has focused on traditional risk factors (hypertension, diabetes and hypercholesterolaemia), risk-prone behaviours (smoking, poor diet and sedentary lifestyles), and impaired access to evidence based care. These factors are important, but not sufficient to fully explain such wide disparity.

The Aboriginal Cardiovascular Omega-3 Trial (AC-Omega 3) is a multi-centre, double-blinded, placebo-controlled randomised trial of 1g/day n-3 PUFA supplementation in Aboriginal patients with established coronary artery disease to determine their effect on factors implicated in adverse CV events including:

1. Atherogenic and protective lipid factors implicated in atherosclerosis

2. Inflammatory factors implicated in atherosclerosis

3. Factors associated with thrombus formation

4. Heart rate variability as a marker of arrhythmic risk

5. Major adverse cardiovascular events (MACE)

This project brings together for the first time a team of investigators with extensive experience across Aboriginal health, lipid, sudden cardiac death, platelet function and fatty acid research spanning basic science through clinical and population health paradigms.This is also the first trial to combine mechanistic research specifically designed to understand the role of lipids, thrombosis, inflammation, endothelial function and n-3 PUFAs in adverse outcomes for vulnerable people, alongside a rigorous RCT of a potentially key therapeutic supplement. It is likely to have importance for understanding the leading cause of death and disparity for Aboriginal people, as well as providing rigorous evidence to guide policy and clinical practice.

Chief Investigators:

Professor Alex Brown, Director of Wardliparingga Aboriginal Research Unit, SAHMRI

Professor Stephen Nicholls, Director of the Vascular Research Centre, SAHMRI

Professor Prashanthan Sanders, Knapman Chair of Cardiology Research, University of Adelaide

Professor Robert Gibson, Professor of Functional Food Science, University of Adelaide

Dr. Scott Willoughby, NHMRC Career Development Fellow, University of Adelaide

Funding Source:

NHMRC Project Grant

Further Information:

For further information contact Helen Loudis

Get in touch
+61 8 8128 4000 info@sahmri.com
You can't miss us!
North Terrace Adelaide 5000 South Australia
Postal Address
PO BOX 11060 Adelaide 5001 South Australia
Key Partners
SAHMRI is located on the traditional lands of the Kaurna Nation.

The SAHMRI community acknowledges and respects the traditional owners, the family clans who are the Kaurna Nation from the Adelaide Plains region of South Australia. We acknowledge the clans of the Kaurna Nation and the sacred knowledge they hold for their country. We pay our respects to the Kaurna Nation, their ancestors and the descendants of these living family clans today.